IceCure Q1 2026 Revenue Up 26% to $911K, U.S. Sales Jump 31%
IceCure Medical’s Q1 2026 revenue rose 26% to $911,000, with U.S. sales up 31% and North America sales climbing 84%, driving gross profit up 35% to $295,000. Active U.S. ProSense® accounts surged 46% post-FDA clearance, fueling new installations and pipeline growth.
1. First Quarter 2026 Financial Results
IceCure Medical reported Q1 2026 revenue of $911,000, up 26% year-over-year from $725,000, with gross profit rising 35% to $295,000. North American sales jumped 84% and U.S. sales increased 31%, driving margin expansion and overall financial momentum.
2. U.S. Commercial Expansion and Account Growth
Following FDA clearance, active U.S. ProSense® accounts increased by 46% to 19 by quarter-end, leading to additional system installations at Thomas Hospital of Infirmary Health and SHERO Imaging. The company accelerated its U.S. commercial footprint across eight regions, converting a growing pipeline of hospitals and clinics.
3. Clinical Milestones and Guidelines Adoption
The ChoICE post-marketing study, approved by the FDA, will involve 30 U.S. hybrid clinical/commercial sites to support broader reimbursement and adoption. Concurrently, the American Society of Breast Surgeons updated guidelines to recommend cryoablation for low-risk breast cancer, bolstering clinical acceptance.
4. Outlook and Pipeline Expansion
IceCure plans to leverage its clinical data—including an 89.4% five-year recurrence-free rate in kidney cancer and a 50% cost reduction versus lumpectomy—to expand ProSense® adoption. Ongoing physician engagement and upcoming industry symposiums are expected to further penetrate hospital networks and drive revenue growth.